Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte Q4 2025 revenue rises 19% to $140.6 million; 2026 guidance reiterated

Positive Impact 3 of 5 earnings Written later

Veracyte reported fourth-quarter 2025 total revenue of $140.6 million, up 19% from a year earlier, and GAAP net income of $41.1 million, or $0.51 per diluted share, compared with $5.1 million, or $0.06, in the prior-year quarter. The company also reiterated its 2026 total revenue guidance of $570 million to $582 million, which shows results improved and the outlook was held steady.

Key points

  • Q4 2025 total revenue was $140.6 million, up 19% from $118.6 million; testing revenue was $135.8 million, up 21%.
  • Q4 2025 GAAP net income was $41.1 million, or $0.51 per diluted share, versus $5.1 million, or $0.06, in Q4 2024.
  • Full-year 2025 total revenue was $517.1 million, up 16%, and GAAP net income was $66.4 million.
  • The company reiterated 2026 total revenue guidance of $570 million to $582 million (10% to 13% growth) and expects adjusted EBITDA margin of about 25%.

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECFeb 25, 2026, 4:07 PM ET
Accession number0001384101-26-000008

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.